Risk of non-alcoholic fatty liver disease in patients with psoriasis: A systematic review and meta-analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 4, 2015, Pages 656-662

  Candia, R ^a   Ruiz, A ^a   Torres Robles, R ^b   Chavez Tapia N ^c   Mendez Sanchez N ^c   Arrese, M ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c LIVER RESEARCH UNIT   (Mexico)

Author keywords

comorbidity; inflammation; liver disease; metabolic syndrome; non alcoholic fatty liver disease; psoriasis; steatosis

Indexed keywords

CASE CONTROL STUDY; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ARTHRITIS, PSORIATIC; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ARTHRITIS, PSORIATIC; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84925399732     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12847     Document Type: Review

References (46)

1. Griffiths CE, Barker JN,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Parker B, Bruce I,. SLE and metabolic syndrome. Lupus 2013; 22; 1259-1266.
3. Pickup JC,. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.
4. Reich K,. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 2): 3-11.
5. Prey S, Paul C, Bronsard V, et al,. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 23-30.
6. Tobin AM, Veale DJ, Fitzgerald O, et al,. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol 2010; 37: 1386-1394.
7. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
8. Riquelme A, Arrese M, Soza A, et al,. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Inter 2009; 29: 82-88.
9. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
10. Angulo P,. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25: 883-889.
11. Clark JM,. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 (Suppl. 1): S5-S10.
12. Adams LA, Lymp JF, St Sauver J, et al,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129; 113-121.
13. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ,. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
14. Harrison SA, Torgerson S, Hayashi PH,. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047.
15. Farias MM, Romero W, Cruz DL,. Metabolic characteristics in Chilean patients with psoriasis. Br J Dermatol 2011; 165: e29.
16. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
17. Scottish Intercollegiate Guidelines Network. Critical appraisal: notes and checklists. [WWW document] 2013. URL http://www.sign.ac.uk/methodology/checklists.html (last accessed: 12 September 2013).
18. Fewell A, Lamb PB, Roberts KK, Battafarano D, Owens NM, Harrison SA,. The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) among patients with psoriasis and psoriatic arthritis in a tertiary care dermatology and rheumatology clinic. Hepatology 2012; 56: 897A.
19. Madanagobalane S, Anandan S,. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012; 53: 190-197.
20. Miele L, Vallone S, Cefalo C, et al,. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
21. Tsai TF, Wang TS, Hung ST, et al,. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63: 40-46.
22. van der Voort EAM, Koehler EM, Dowlatshahi EA, et al,. Psoriasis is independently associated with nafld: results from a population-based study. Nederlands Tijdschrift voor Dermatologie en Venereologie 2013; 23: 57-58.
23. van der Voort EA, Koehler EM, Dowlatshahi EA, et al,. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 2014; 70: 517-524.
24. Wenk KS, Arrington KC, Ehrlich A,. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-391.
25. Anstee QM, Targher G, Day CP,. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344.
26. Langman G, Hall PM, Todd G,. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001; 16: 1395-1401.
27. Rosenberg P, Urwitz H, Johannesson A, et al,. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118.
28. Miller IM, Ellervik C, Zarchi K, et al,. The association of metabolic syndrome and psoriasis: a population- and hospital-based cross-sectional study. J Eur Acad Dermatol Venereol 2014; doi: 10.1111/jdv.12595. [Epub ahead of print].
29. Danielsen K, Wilsgaard T, Olsen AO, et al,. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and gender differences. Br J Dermatol 2014; doi: 10.1111/bjd.13288. [Epub ahead of print].
30. Trauner M, Arrese M, Wagner M,. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010; 1801: 299-310.
31. Boehncke S, Thaci D, Beschmann H, et al,. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-1251.
32. Karadag AS, Yavuz B, Ertugrul DT, et al,. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol 2010; 49: 642-646.
33. Xue K, Liu H, Jian Q, et al,. Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro: a possible reason for increased severity of psoriasis in patients with a high body mass index. Exp Dermatol 2013; 22: 406-410.
34. Russolillo A, Iervolino S, Peluso R, et al,. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford) 2013; 52: 62-67.
35. Chen YJ, Wu CY, Shen JL, et al,. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol 2008; 144: 1571-1575.
36. Gerdes S, Rostami-Yazdi M, Mrowietz U,. Adipokines and psoriasis. Exp Dermatol 2011; 20: 81-87.
37. Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U,. Leptin, adiponectin, visfatin and retinol-binding protein-4: mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012; 21: 43-47.
38. Kadry D, Hegazy RA, Rashed L,. Osteopontin and adiponectin: how far are they related in the complexity of psoriasis? Arch Dermatol Res 2013; 305: 939-944.
39. Itoh S, Kanazuka A, Akimoto T,. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003; 48: 2182-2186.
40. Itoh S, Kono M, Akimoto T,. Psoriasis treated with ursodeoxycholic acid: three case reports. Clin Exp Dermatol 2007; 32: 398-400.
41. Campanati A, Ganzetti G, Di Sario A, et al,. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-846.
42. Ramos AN, de Oliveira Rocha B, de Almeida Rego VR, Follador I, de Oliveira MF,. The linkage between psoriasis and non-alcoholic fatty liver disease: a literature review. Acta Dermatovenerol Croat 2014; 22: 132-136.
43. Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al,. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr 2014; 105: 31-44.
44. Rattanakaemakorn P, Fleischer AB,. Psoriasis or obesity is a risk factor for nonalcoholic fatty liver disease. J Am Acad Dermatol 2014; 71: 588.
45. The Cochrane Collaboration. In, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. URL http://handbook.cochrane.org/chapter-9/9-6-4-meta-regression.htm (last accessed: 12 September 2013).
46. Nascimbeni F, Loria P, Ratziu V,. Non-alcoholic fatty liver disease: diagnosis and investigation. Dig Dis 2014; 32: 586-596.